What is Innocoll Holdings?
Founded in 1985 and headquartered in Athlone, Ireland, Innocoll Holdings operates as a global specialty pharmaceutical entity focused on the development of biocompatible and biodegradable collagen products. By leveraging advanced material science, the company engineers targeted medical solutions designed to improve clinical outcomes. Its market position is defined by a robust portfolio of late-stage development programs that address critical therapeutic needs. The firm's unique approach to drug delivery and tissue repair positions it as a key player in the specialty medicine landscape, bridging the gap between traditional pharmaceutical manufacturing and innovative biotechnology applications.
How much funding has Innocoll Holdings raised?
Innocoll Holdings has raised a total of $213.5M across 3 funding rounds:
Private Equity
$30M
Stock Offering
$58.5M
Debt
$125M
Private Equity (2007): $30M, investors not publicly disclosed
Stock Issuance/Offering (2014): $58.5M, investors not publicly disclosed
Debt (2022): $125M supported by Oaktree
Key Investors in Innocoll Holdings
Oaktree
Oaktree Capital Management is a leading global investment management firm specializing in alternative investments, recognized for its opportunistic and value-oriented approach to credit and equity markets.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Innocoll Holdings?
With the recent infusion of capital, Innocoll Holdings is well-positioned to accelerate its late-stage clinical programs and optimize its manufacturing capabilities for its proprietary collagen technologies. The strategic focus will likely shift toward regulatory milestones and the commercialization of its pipeline assets. By maintaining a disciplined approach to research and development, the company aims to solidify its competitive advantage in the specialty pharma market. Future growth will be driven by the successful transition of its engineered medicines from the laboratory to clinical application, ensuring that the firm remains at the forefront of therapeutic innovation while delivering long-term value to its stakeholders and the broader medical community.
See full Innocoll Holdings company page
